Shares of Humacyte Inc (NASDAQ: HUMA) nearly doubled on Friday after receiving full approval for its flagship SYMVESS product from the US Food and Drug Administration (FDA). Regulatory approval for the company’s bioengineered human tissue marks a major step forward in regenerative medicine and trauma care. Humacyte stock sure has…
Bloomberg reports Nike Inc. is bracing for a turbulent phase as new Chief Executive Officer Elliott Hill leads efforts…
Professional investors have long held significant advantages over individual investors. They have vast resources at their disposal, including technology,…
GameStop (GME) stock price has moved sideways in the past few months as investors assess its slow business trajectory…
Thwarted expectations of up to 4 rate cuts in 2025 have sent US stocks tumbling down in recent days.…
Indian shares were wobbly at the time of opening on Friday. Nifty and Sensex continued their downward trend for…
Asian equities remained on edge on Friday, as market participants awaited the release of key US inflation data for…